Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Insulin vs Amniotic Membrane Transplant in Persistent Corneal Epithelial Defects
NCT07561398Phase 4Recruiting
- Sponsor
- Al-Shifa Trust Eye Hospital
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Generex Oral-lyn in persistent corneal epithelial defect (PED) (2 arms), sponsored by Al-Shifa Trust Eye Hospital. Primary endpoint: Cure rate at 24 weeks. Started Mar 2026; status: recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT07561398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561398.